Literature DB >> 19358437

Imaging after radiofrequency ablation of hepatic tumors.

Young-Sun Kim1, Hyunchul Rhim, Hyo Keun Lim.   

Abstract

Radiofrequency ablation (RFA) is now increasingly used as a first-line therapeutic modality for small malignant hepatic tumors in many parts of the world. The importance of radiological imaging at follow-up to assess therapeutic effectiveness, presence of complications, and recurrences cannot be overemphasized, as RFA treatment is minimally invasive and locally applied. A broad spectrum of imaging findings obtained by the use of various modalities has been reported by many investigators. In this review, we describe findings, including chronologic changes of the ablation zones, both local and remote recurrences, and complications that occur after RFA of the liver as well as the advantages and disadvantages of the use of each imaging modality for a specific situation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358437     DOI: 10.1053/j.sult.2008.12.004

Source DB:  PubMed          Journal:  Semin Ultrasound CT MR        ISSN: 0887-2171            Impact factor:   1.875


  9 in total

1.  Imaging to optimize liver tumor ablation.

Authors:  Bradley B Pua; Constantinos T Sofocleous
Journal:  Imaging Med       Date:  2010-08

Review 2.  Complications after Thermal Ablation of Hepatocellular Carcinoma and Liver Metastases: Imaging Findings.

Authors:  Federica De Muzio; Carmen Cutolo; Federica Dell'Aversana; Francesca Grassi; Ludovica Ravo; Marilina Ferrante; Ginevra Danti; Federica Flammia; Igino Simonetti; Pierpaolo Palumbo; Federico Bruno; Luca Pierpaoli; Roberta Fusco; Andrea Giovagnoni; Vittorio Miele; Antonio Barile; Vincenza Granata
Journal:  Diagnostics (Basel)       Date:  2022-05-05

3.  Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.

Authors:  Susanne Bonekamp; Zhen Li; Jean-François H Geschwind; Vivek Gowdra Halappa; Celia Pamela Corona-Villalobos; Diane Reyes; Timothy M Pawlik; David Bonekamp; John Eng; Ihab R Kamel
Journal:  Radiology       Date:  2013-04-24       Impact factor: 11.105

4.  Interventional radiological treatment of hepatocellular carcinoma: an update.

Authors:  Anurag Shrimal; Madhu Prasanth; A V Kulkarni
Journal:  Indian J Surg       Date:  2011-12-13       Impact factor: 0.656

Review 5.  MRI assessment of hepatocellular carcinoma after locoregional therapy.

Authors:  Rasha S Hussein; Wahid Tantawy; Yasser A Abbas
Journal:  Insights Imaging       Date:  2019-01-29

6.  Rim Enhancement after Technically Successful Transarterial Chemoembolization in Hepatocellular Carcinoma: A Potential Mimic of Incomplete Embolization or Reactive Hyperemia?

Authors:  Kaspar Ekert; Christopher Kloth; Konstantin Nikolaou; Gerd Grözinger; Marius Horger; Wolfgang Thaiss
Journal:  Tomography       Date:  2022-04-15

Review 7.  RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline.

Authors:  Els L van Persijn van Meerten; Hans Gelderblom; Johan L Bloem
Journal:  Eur Radiol       Date:  2009-12-22       Impact factor: 5.315

Review 8.  CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review.

Authors:  Daniel Marin; Salvatore Cappabianca; Nicola Serra; Assunta Sica; Francesco Lassandro; Roberto D'Angelo; Michelearcangelo La Porta; Francesco Fiore; Francesco Somma
Journal:  Gastroenterol Res Pract       Date:  2015-12-22       Impact factor: 2.260

Review 9.  Gastrointestinal tract injuries after thermal ablative therapies for hepatocellular carcinoma: A case report and review of the literature.

Authors:  Teresa Marzia Rogger; Andrea Michielan; Sandro Sferrazza; Cecilia Pravadelli; Luisa Moser; Flora Agugiaro; Giovanni Vettori; Sonia Seligmann; Elettra Merola; Marcello Maida; Francesco Antonio Ciarleglio; Alberto Brolese; Giovanni de Pretis
Journal:  World J Gastroenterol       Date:  2020-09-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.